See more : Hunyvers SA (ALHUN.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Emerald Health Therapeutics, Inc. (EMHTF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Emerald Health Therapeutics, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Get Real USA, Inc. (GTRL) Income Statement Analysis – Financial Results
- Micronet Ltd (MCRNT.TA) Income Statement Analysis – Financial Results
- eBay Inc. (EBAY) Income Statement Analysis – Financial Results
- Tsugami Corporation (6101.T) Income Statement Analysis – Financial Results
- VNET Group, Inc. (VNET) Income Statement Analysis – Financial Results
Emerald Health Therapeutics, Inc. (EMHTF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://emeraldhealth.ca
About Emerald Health Therapeutics, Inc.
Emerald Health Therapeutics, Inc., together with its subsidiaries, engages in the production, distribution, and sale of recreational and medical cannabis in Canada. It offers dried cannabis strains, pre-rolled cannabis, oral sprays, nano emulsion shots, and cannabis oil products under the SYNC Wellness, fuse, Emerald, and Souvenir brands. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Vancouver, Canada. As of November 10, 2022, Emerald Health Therapeutics, Inc. operates as a subsidiary of Skye Bioscience, Inc.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.68M | 11.74M | 20.32M | 1.95M | 937.65K | 253.32K | 31.29K | 0.00 | 117.55K | 233.74K | 46.57K | 0.00 | 0.00 |
| Cost of Revenue | 16.14M | 21.41M | 34.79M | 5.05M | 1.22M | 603.27K | 203.80K | 0.00 | 53.18K | 94.17K | 17.25K | 0.00 | 0.00 |
| Gross Profit | -6.46M | -9.67M | -14.47M | -3.10M | -285.52K | -349.95K | -172.51K | 0.00 | 64.37K | 139.57K | 29.32K | 0.00 | 0.00 |
| Gross Profit Ratio | -66.72% | -82.37% | -71.21% | -159.06% | -30.45% | -138.14% | -551.31% | 0.00% | 54.76% | 59.71% | 62.96% | 0.00% | 0.00% |
| Research & Development | 1.73M | 1.57M | 4.28M | 801.35K | 207.50K | 301.53K | 162.32K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 8.92M | 12.44M | 26.04M | 21.49M | 7.89M | 1.90M | 2.76M | 1.88M | 94.87K | 77.47K | 60.25K | 26.42K | 63.62K |
| Selling & Marketing | 2.37M | 1.56M | 4.37M | 11.33M | 428.54K | 271.12K | 360.79K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.29M | 14.00M | 30.41M | 32.83M | 8.32M | 2.17M | 3.12M | 1.88M | 94.87K | 77.47K | 60.25K | 26.42K | 63.62K |
| Other Expenses | 1.25M | 1.76M | 1.85M | 618.44K | 282.45K | 116.35K | 46.41K | 20.19K | 57.97K | 70.02K | 14.30K | 0.00 | 0.00 |
| Operating Expenses | 14.27M | 17.33M | 36.54M | 34.25M | 8.81M | 2.59M | 3.32M | 1.90M | 152.84K | 147.49K | 74.55K | 26.42K | 63.62K |
| Cost & Expenses | 30.41M | 38.74M | 71.33M | 39.29M | 10.03M | 3.19M | 3.53M | 1.90M | 206.01K | 241.66K | 91.80K | 26.42K | 63.62K |
| Interest Income | 298.00K | 1.28M | 952.88K | 1.19M | 161.52K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 451.00 | 1.90K |
| Interest Expense | 700.00K | 4.97M | 765.64K | 218.60K | 0.00 | 39.68K | 0.00 | 0.00 | 52.08K | 63.04K | 13.00K | 154.00 | 0.00 |
| Depreciation & Amortization | 2.85M | 4.82M | 6.43M | 3.45M | 282.45K | 116.35K | 46.41K | 20.19K | 61.66K | 70.02K | 14.30K | 605.00 | 1.90K |
| EBITDA | -35.61M | -32.96M | -105.81M | -26.93M | -8.45M | -2.78M | -3.45M | -2.62M | -30.50K | 62.10K | -30.93K | -25.97K | -61.83K |
| EBITDA Ratio | -367.94% | -280.78% | -520.74% | -1,382.37% | -901.12% | -1,099.19% | -11,028.29% | 0.00% | -25.94% | 26.57% | -66.41% | 0.00% | 0.00% |
| Operating Income | -38.47M | -37.78M | -112.24M | -30.38M | -8.73M | -2.90M | -3.50M | -2.65M | -92.16K | -7.93K | -45.23K | -26.58K | -63.73K |
| Operating Income Ratio | -397.43% | -321.83% | -552.38% | -1,559.31% | -931.24% | -1,145.12% | -11,176.60% | 0.00% | -78.40% | -3.39% | -97.11% | 0.00% | 0.00% |
| Total Other Income/Expenses | -700.00K | -5.56M | -164.02M | -625.12K | -109.99K | -39.68K | 0.00 | 0.00 | -52.08K | -63.04K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -39.17M | -43.34M | -113.01M | -31.01M | -8.84M | -2.94M | -3.50M | -2.65M | -144.24K | -70.97K | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -404.66% | -369.19% | -556.15% | -1,591.39% | -942.97% | -1,160.78% | -11,176.60% | 0.00% | -122.70% | -30.36% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 700.00K | 196.00K | -1.10M | -23.61K | -109.99K | 39.68K | 0.00 | 0.00 | 52.08K | 63.04K | 13.00K | -605.00 | -1.90K |
| Net Income | -39.87M | -43.54M | -111.91M | -30.98M | -8.73M | -2.98M | -3.50M | -2.65M | -196.32K | -134.01K | -58.22K | -25.97K | -61.83K |
| Net Income Ratio | -411.89% | -370.86% | -550.74% | -1,590.18% | -931.24% | -1,176.44% | -11,176.60% | 0.00% | -167.01% | -57.33% | -125.02% | 0.00% | 0.00% |
| EPS | -0.21 | -0.23 | -0.76 | -0.22 | -0.10 | -0.05 | -0.08 | -0.07 | -0.10 | -0.07 | -0.03 | -0.05 | -0.21 |
| EPS Diluted | -0.21 | -0.23 | -0.76 | -0.22 | -0.10 | -0.05 | -0.08 | -0.07 | -0.10 | -0.07 | -0.03 | -0.05 | -0.21 |
| Weighted Avg Shares Out | 193.21M | 193.21M | 147.96M | 141.44M | 88.45M | 54.26M | 46.07M | 37.08M | 2.01M | 2.01M | 2.00M | 487.20K | 298.60K |
| Weighted Avg Shares Out (Dil) | 193.21M | 193.21M | 147.96M | 141.44M | 88.45M | 54.26M | 46.07M | 37.08M | 2.01M | 2.01M | 2.00M | 487.20K | 298.60K |
Skye Bioscience concludes merger with Emerald Health Therapeutics and unveils goals for 2022 and 2023
Skye Bioscience Inc (OTCQB:SKYE) announced that it has concluded the merger with Emerald Health Therapeutics after both companies' shareholders voted in favor and the Supreme Court of British Columbia approved the transaction. As of the date of closing, Skye has...
Skye Bioscience says Emerald Health Therapeutics shareholders approve integration plan of arrangement; gets regulatory approval to begin first-in-human clinical study
Skye Bioscience Inc (OTCQB:SKYE) has announced that the shareholders of Emerald Health Therapeutics Inc (CSE:EMH, OTCQX:EMHTF) have approved the proposed plan of arrangement which will result in the integration of the two companies, and also revealed regulatory approval to begin its...
Skye Bioscience signs agreement to merge with Emerald Health Therapeutics
Skye Bioscience Inc (OTCQB:SKYE) and Emerald Health Therapeutics Inc said they have entered into a definitive agreement that will see Skye acquiring Emerald in a share-for-share transaction. Under the proposed plan of arrangement, Skye will issue Emerald shareholders 1.95 shares of...
Emerald Health Therapeutics Leaving 'Saturated' Cannabis Market, Will Focus On Pharmaceuticals
Emerald Health Therapeutics, Inc. (CSE:EMH) (OTCQX:EMHTF) announced Monday that it is getting out of the recreational and medical cannabis industry and pivoting to pharmaceutical development. The company also announced its president and CEO, Riaz Bandali has resigned.
Emerald Health Therapeutics Announces Chief Financial Officer Transition
Vancouver, British Columbia--(Newsfile Corp. - September 10, 2021) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald") announced today that its Chief Financial Officer, Jenn Hepburn, will be stepping down from her position at Emerald, effective October 15, 2021,...
Emerald Health Therapeutics, Inc. (EMHTF) CEO Riaz Bandali on Q2 2021 Results - Earnings Call Transcript
Emerald Health Therapeutics, Inc. (EMHTF) CEO Riaz Bandali on Q2 2021 Results - Earnings Call Transcript
Emerald Health Therapeutics Reports 2021 Second Quarter Financial Results and Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - August 31, 2021) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald") has released its financial results for the three and six months ended June 30, 2021. Full versions of Emerald's unaudited condensed interim...
Emerald Health Therapeutics to Host 2021 Second Quarter Financial Results Conference Call on Tuesday, August 31, 2021 at 10:30 AM ET
Vancouver, British Columbia--(Newsfile Corp. - August 25, 2021) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald") today announced that it will report its financial results for the second quarter ended June 30, 2021, after the market close on Monday, August...
Emerald Health Therapeutics Hires VP Sales & Marketing
Vancouver, British Columbia--(Newsfile Corp. - August 10, 2021) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald") has appointed Nick Mosgrove as VP Sales & Marketing. Mr. Mosgrove has over 15 years of sales and marketing leadership experience in...
Emerald Health Therapeutics Executive Chairman Avtar Dhillon Resigns
Vancouver, British Columbia--(Newsfile Corp. - August 6, 2021) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald") today announced that Avtar Dhillon, MD, has resigned from his roles as director and Executive Chairman of Emerald's board of directors for...
Source: https://incomestatements.info
Category: Stock Reports